Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings Routine +

Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update

Spectral Medical Advances PMA Submission While Cash Burn Rate Demands Immediate Capital Attention

By The Northwire Desk — AI Analysis May 08, 2026 · 07:30 EDT · 1.36 SPECTRAL MEDICAL INC.
Executive Summary
  • Spectral Medical reported Q1 2026 financial results with revenue increasing 56% year-over-year to $891,000.
  • Net loss narrowed significantly to $2,938,000 ($0.01 per share) compared to a $12,605,000 loss in Q1 2025.
  • Operating expenses decreased 72% year-over-year primarily due to lower non-cash fair value adjustments on derivative liabilities.
  • The company set a target date of May 29, 2026, for its U.S. FDA Premarket Approval (PMA) application submission for Toraymyxin™ (PMX).
  • Clinical validation was strengthened by the publication of the Tigris trial in The Lancet Respiratory Medicine, confirming positive mortality benefits.
  • Vantive US Healthcare LLC agreed to advance $1.0 million of a $2.0 million Tranche D funding ahead of the PMA acceptance milestone.
  • Cash and cash equivalents ended the quarter at $1,918,000, down from $4,071,000 at year-end 2025.
Material Impact
  • The news confirms the regulatory timeline previously outlined in February and March updates (late April to mid-May window), validating management's execution on the PMA submission strategy.
  • Revenue growth of 56% is positive but remains immaterial in absolute terms ($891k) for a company with this burn rate, indicating commercial traction is still nascent.
  • The significant reduction in net loss is largely driven by non-cash accounting adjustments (derivative liabilities), which masks the underlying operational cash burn risk.
  • Vantive's advance of $1 million provides temporary liquidity relief but does not fully solve the runway issue given the quarterly operating expense of $3.6 million.
  • The market impact is expected to be incremental rather than transformative, as the PMA submission date was anticipated and clinical data has already been published in March.
EDT · Price
Company Overview
  • Company: Spectral Medical Inc., a clinical-stage biotechnology company focused on septic shock treatment.
  • Flagship Project: Toraymyxin™ (PMX), a polymyxin B hemoadsorption device designed to remove endotoxins from the blood of patients with endotoxic septic shock.
  • Development Status: Phase 3 Tigris trial completed; PMA submission targeted for late May 2026.
  • Clinical Data: Tigris trial showed a 95.3% probability of benefit for 28-day mortality and 99.4% for 90-day mortality with absolute risk reductions of 10.3% and 15.5% respectively.
Read the original news release →

More from SPECTRAL MEDICAL INC.

Jun 25, 2026 · 07:00

Spectral Medical Announces U.S. FDA Filing of PMA Application for PMX

Regulatory Jun 04, 2026 · 07:00

Spectral Medical and Vantive Announce Topline 12 Month Follow-Up Results From Spectral's Tigris Trial

Regulatory May 29, 2026 · 07:00

Spectral Medical Files FDA PMA for PMX Amidst Tight Cash Runway

Regulatory Mar 26, 2026 · 07:30

Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update

Earnings Mar 24, 2026 · 12:28

Spectral, Vantive release Tigris results in Lancet

Regulatory Mar 24, 2026 · 07:00

Spectral Medical and Vantive Announce Publication of Complete Results from Spectral's Tigris Trial in the Lancet Respiratory Medicine

Other